Business Wire

Celltrion Healthcare: Switching to Remsima®▼ (infliximab) from originator has no negative effect on safety or efficacy in 10 real-world studies

18.3.2016 11:20 | Business Wire

Del

Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight countries show comparable efficacy and safety following a switch to biosimilar infliximab from originator infliximab.1-10 These studies, presented at the 11th Congress of the European Crohn’s and Colitis Organisation (ECCO), further support the appropriate switching of patients to Remsima®, a cost-effective alternative to originator infliximab, and build on the wealth of real-world evidence of the safety and efficacy of Remsima® accumulated since its launch a year ago.

As physician experience with biosimilar infliximab has grown, so has confidence in monoclonal antibody biosimilars. The results of a survey of ECCO members presented at the ECCO congress show that only 19.5% of respondents feel little or no confidence in the use of biosimilar monoclonal antibodies compared to 61% of respondents to a previous version of the survey undertaken in 2013.11 The survey also shows that positive switching studies with biosimilar infliximab have helped to reassure physicians about switching from the originator, with 44.4% of respondents considering the originator and biosimilar to be interchangeable, compared with only 6% in the 2013 survey.

Professor Silvio Danese, head of the IBD Center at the Istituto Clinico Humanitas and lead author of the survey, said: “Biosimilar infliximab was the first monoclonal antibody to become available so there was some understandable trepidation around the time of launch. However, as people have been able to use the treatment, and with the large number of real-world and post-marketing studies now available, increasing numbers of clinicians are confident to use monoclonal antibody biosimilars. It is important that post-marketing and longer term studies with biosimilar infliximab are reported in order to further reassure clinicians and patients about biosimilars.”

The positive results of the biosimilar infliximab switching studies are further supported by two long-term follow up studies presented today at a Celltrion Healthcare satellite symposium. The extension studies of PLANETAS12 and PLANTETRA13 – the phase 3 trials that supported the approval of Remsima® – were performed to investigate the efficacy and safety of maintenance treatment with Remsima® over two years as well as the efficacy and safety of switching to Remsima® from originator infliximab for one year. Clinical efficacy, immunogenicity and safety were highly comparable between the maintenance and switch groups in both extension studies. Importantly, there were no signs of altered efficacy, safety or immunogenicity profiles following the switch to Remsima® from the originator. Furthermore, the proportion of immunogenicity-related safety events was similar between maintenance and switched rheumatoid arthritis and ankylosing spondylitis patients.

Man Hoon Kim, President and CEO of Celltrion Healthcare, said: “We know that physicians value real-world as well as clinical evidence and have worked hard to ensure these data are available. We now have a remarkable volume of data showing the comparable safety and efficacy of Remsima® in both treatment-naïve patients and those who have been switched to Remsima® from originator infliximab. We’re delighted to see a corresponding growth in physician confidence with monoclonal antibody biosimilars, and in willingness to switch to a biosimilar from the originator. This suggests that more patients will get the chance to benefit from biological therapies, particularly for conditions that require chronic treatment such as IBD.”

--- Ends---

Notes to editors:

About the switching studies

Abstract   Title   Authors   # of switched patients
DOP029 Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab F. Cummings, et al. 134

(indications unclassified)

DOP030 Elective switching from Remicade® to biosimilar CT-P13 in Inflammatory Bowel Disease patients: A prospective observational cohort study L. Smits, et al. 83

(CD: 57 UC: 24 Unclassified IBD: 2)

DOP032 Switching of patients with Inflammatory Bowel Disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima®) is effective and safe M. Kolar, et al. 74

(CD: 56, UC: 18)

P329 Infliximab biosimilar in the treatment of Inflammatory Bowel Disease: A Japanese single cohort observational study S. Hamanaka, et al. 3

(CD: 2, UC: 1)

P449 Efficacy and safety of switching between originator and biosimilar infliximab in patients with Inflammatory Bowel Disease in practical clinic: Results to 6 months L. Díaz Hernández, et al. 72

(CD: 62, UC: 10)

P452 Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn’s Disease patients in clinical practice: Results after 6 months’ treatment M.F. Guerra Veloz, et al. 71

(CD)

P544 Prospective observational study on IBD patients treated with infliximab biosimilars: Preliminary results of the PROSIT-BIO cohort of the IG-IBD N. Manetti, et al. 97

(IBD)

P600 Safety and efficacy of infliximab biosimilar (Remsima©) in Ulcerative Colitis disease patients in clinical practice: Results after 6 months treatment M.F. Guerra Veloz, et al. 31

(UC)

P617 Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn disease J. Sieczkowska, et al. 16

(paediatric CD)

P655 Biosimilar infliximab CT-P13 treatment in patients with Inflammatory Bowel Diseases: A one year, single-center retrospective study T. Hlavaty, et al. 12

(CD: 10, UC: 2)

Further data for biosimilar infliximab presented at the 11 th Congress of ECCO

  • OP003 P.A. Golovics, et al. Predicting short and medium-term efficacy of the biosimilar infliximab: trough levels/ADAs or clinical/biochemical markers play a more important role?
  • DOP010 A. Bálint, et al. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
  • DOP028 K. Gecse, et al. Efficacy and safety of biosimilar infliximab after one year: results from a prospective nationwide cohort.
  • DOP031 R. Bor, et al. Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in ulcerative colitis – data from two Central European countries.
  • DOP033 B. Lovasz, et al. Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort.
  • P311 D. Duricova, et al. No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: Short-term results.
  • P327 L. Carvalho Lourenço, et al. Biosimilar infliximab in real-life Crohn’s disease’s anti-TNF alpha naïve patients: a comparative observational cohort study (SIMRECRO study).
  • P382 R. Muhammed, et al. Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel disease.
  • P484 P. Lakatos, et al. Access to biologics and biosimilars across 11 EU countries.
  • P495 M. Bortlik, et al. Biosimilar infliximab is effective and safe in inflammatory bowel disease patients naïve to antiTNF therapy: a tertiary centre experience.
  • P513 E. Zagorowicz, et al. Comparison of infliximab the originator and biosimilars in treatment of Crohn’s Disease: a Polish cohort study.
  • P519 M. Kaniewska, et al. Efficacy and safety of biosimilar of infliximab (Inflectra) in adult patients with Crohn’s disease during one year of treatment followed by 6 months of observation – one centre retrospective study.
  • P530 J. Sieczkowska, et al. Efficacy of biosimilar infliximab induction therapy in paediatric patients with Crohn’s Disease –1.5 years of experience.
  • P577 N. Turk, et al. Croatian database from 5 centers – efficacy and safety of infliximab biosimilar in treatment of IBD patients.
  • P645 M. Kaniewska, et al. Efficacy and safety of biosimilar of infliximab in rescue therapy in adult patients with severe ulcerative colitis.

About inflammatory bowel diseases

Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disabling gastrointestinal disorders that impact every aspect of a patient’s life. They affect an estimated 2.5-3 million people in Europe;14 CD affects about three people per 1,000 and UC about 5 people per 1,000.16

IBDs account for substantial costs to the healthcare system and society; the direct healthcare costs of IBDs are estimated to be €4.6-5.6 billion per year.17

About biosimilar infliximab

The biosimilar infliximab developed and manufactured by Celltrion, Inc. is the world’s first biosimilar monoclonal antibody to be approved by the European Medicines Agency (EMA) for treatment of eight autoimmune diseases. It was approved by the EMA under the trade name Remsima® in September 2013 and launched in Europe in early 2015. It is currently being reviewed by the U.S. FDA with the FDA Arthritis Advisory Committee recommending approval of all indications of Celltrion’s biosimilar infliximab in February 2016.

About Celltrion Healthcare

Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries, including both developed and emerging markets. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA’s cGMP and the EMA’s GMP standards. For more information please visit: www.celltrionhealthcare.com/

Celltrion Healthcare has established a vast distribution network of partners and experts who have in-depth knowledge and experience in their local markets. In European markets, Celltrion Healthcare is in partnership with the following companies:

  • Astro Pharma: Austria
  • Biogaran: France and Monaco
  • DEMO S.A.: Cyprus
  • Egis: Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Moldova, Bulgaria, Czech Republic, Latvia, Lithuania, Poland, Romania, Slovakia, Russia, Ukraine, Uzbekistan and Hungary.
  • Hospira: Europe
  • Iceland: Portfarma
  • Kern Pharma: Spain
  • Medical Logistics: Malta
  • Mundipharma: Belgium, Germany, Italy, Luxembourg, the Netherlands and the UK (Napp)
  • Oktal Pharma d.o.o: Slovenia, Croatia, Bosnia-Herzegovina and Serbia
  • Orion: Denmark, Estonia, Finland, Norway, and Sweden
  • PharmaKern: Portugal
  • Pinewood: Ireland
  • Switzerland: iQone Healthcare

References

1 Cummings F, et al. Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab. 11th Congress of ECCO. DOP029.

2 Smits L, et al. Elective switching from Remicade® to biosimilar CT-P13 in Inflammatory Bowel Disease patients: A prospective observational cohort study. 11th Congress of ECCO. DOP030.

3 Kolar M, et al. Switching of patients with Inflammatory Bowel Disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe. 11th Congress of ECCO. DOP032.

4 Diaz Hernández L, et al. Efficacy and safety of switching between originator and biosimilar infliximab in patients with Inflammatory Bowel Disease in practical clinic: Results to 6 months. 11th Congress of ECCO. P449.

5 Sieczkowska J, et al. Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn disease. 11th Congress of ECCO. P617.

6 Hamanka S, et al. Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single-cohort observational study. 11th Congress of ECCO. P329.

7 Guerra Veloz MF, et al. Safety and efficacy of infliximab biosimilar (Remsima) in Crohn’s disease patients in clinical practice: results after 6 months of treatment. 11th Congress of ECCO. P452.

8 Fiorino G, et al. Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD. 11th Congress of ECCO. P544.

9 Guerra Veloz MF, et al. Safety and efficacy of infliximab biosimilar (Remsima) in ulcerative colitis disease patients in clinical practice: results after 6-months treatment. 11th Congress of ECCO. P600.

10 Hlavaty T, et al. Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases: a 1-year, single-centre retrospective study. 11th Congress of ECCO. P655.

11 Danese S, et al. Has IBD specialists’ awareness of biosimilar monoclonal antibodies changed? Results from a survey among ECCO members. 11th Congress of ECCO. P312.

12 Park W, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605-12. Available at: ard.bmj.com/content/early/2013/05/16/annrheumdis-2012-203091.full [accessed March 2016].

13 Yoo D H, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613-20. Available at: ard.bmj.com/content/early/2013/05/20/annrheumdis-2012-203090.full.pdf [accessed March 2016].

14 Burisch J, et al. The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis (2013)7,322-337.

Contact information

Hanover Communications for Celltrion Healthcare
Frances Beves
fbeves@hanovercomms.com
+44-7496-622-326
or
Andra Voinea
avoinea@hanovercomms.com
+44-7475-145-651

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Westinghouse to Provide Fuel to PSEG’s Salem Nuclear Generating Station Through Continued Partnership23.8.2017 12:15Pressemelding

Westinghouse Electric Company today announced that it has signed a nuclear fuel contract extension with PSEG, a major supplier of nuclear power in New Jersey, to continue providing fuel assemblies for both units at the Salem Nuclear Generating Station. “Westinghouse has been the single-source fuel provider for PSEG’s Salem plant since its start of operations more than 40 years ago, and we are pleased to continue to support this important and long-standing customer through the delivery of safe, reliable high-performance fuel,” said David Howell, president, Americas Region, and chief growth officer at Westinghouse. “This continued partnership is recognition of our reliable fuel performance and confirmation of the important trust PSEG has in Westinghouse.” Under the terms of the contract, Westinghouse will deliver its 17x17 Robust Fuel Assemblies, known as RFA-2. The design of

GN Hearing Announces Availability of Rechargeable Solution for the Recently Launched ReSound LiNX 3D23.8.2017 12:00Pressemelding

GN Hearing introduces a rechargeable battery option for the revolutionary ReSound LiNX 3D hearing aids. Available in North America and other major markets from September 1, the rechargeable battery solution gives ReSound users even more options to choose from. The rechargeable option is also available for Beltone Trust in North America, and from September 1 this will be extended to other major markets. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005211/en/ GN Hearing has made a rechargeable battery option available for the revolutionary ReSound LiNX 3D hearing aids. (Photo: Business Wire) ReSound LiNX 3D Rechargeable – More Than Just Another Rechargeable Hearing Aid The rechargeable battery option is made available based on a deep understanding of user expectations

EURid Supports Uganda Borehole Rehabilitation Project23.8.2017 09:00Pressemelding

EURid has announced its support to the Borehole Rehabilitation project in Uganda to provide thousands of people with clean drinkable water. EURid sees water as the most basic requirement for life. For many rural communities across Sub-Saharan Africa it is still a struggle to find safe drinking water. Moreover, water drawn from rivers could potentially contain lethal contaminants and therefore must be boiled before ingestion, adding yet an additional hardship for families as well as the environment in terms of firewood used. The goal of the Borehole Rehabilitation project is to better this situation by working with Ugandan communities to repair broken boreholes and restore access to clean, safe drinking water. The direct benefits of the project are that families no longer have to travel great distances to attain water or boil the water to eradicate contaminants, saving firewood and prev

His Highness Sheikh Mohammed bin Rashid Al Maktoum Unveils Blueprint for Dubai Food Park23.8.2017 07:00Pressemelding

His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, has unveiled the blueprint for Dubai Food Park (DFP), the latest addition to Dubai Wholesale City (DWSC). This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005041/en/ Central Wholesale Market within Dubai Food Park (Photo: AETOS Wire) To be developed at a cost of US$1.5 billion, first destination in the Middle East dedicated to serving the food sector. DFP seeks to enhance Dubai’s position as a leading regional hub for food trade, import, export and re-export of foodstuffs. Conceptualized at a time when food trade makes up 11 percent of the UAE’s GDP and the food industry is estimated to grow by 70 percent to US$6.3 billion by 2030, the Park will offer all categories of f

Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients23.8.2017 06:00Pressemelding

Octapharma is delighted to announce the publication of interim data from the NuProtect study (GENA-05, NCT01712438), the first clinical data on treatment with Nuwiq® in previously untreated patients (PUPs), on August 16th 2017 as an Early View article in the internationally renowned medical journal Haemophilia. The NuProtect study was initiated in March 2013 to investigate the immunogenicity, efficacy and safety of Nuwiq® in PUPs with severe haemophilia A, who are at the greatest risk of developing inhibitors. The ongoing study has enrolled 110 PUPs of any age or ethnicity who will receive Nuwiq® for up to 100 exposure days (EDs), making it one of the largest studies with a single FVIII product. Patients who previously received any FVIII concentrates or blood products containing FVIII are excluded from the study. The recently published article describes interim results for 6

IBC’s Big Screen to Explore the Future of Camera and Display Technologies and the Business Behind Cinema22.8.2017 16:58Pressemelding

IBC today announced the details of its Big Screen programme, taking place in a specially built auditorium designed to IBC’s specifications and featuring the very latest in cinema technology. With the latest Dolby Vision dramatic imaging and Dolby Atmos immersive audio sound installation, the four-day programme examines and demonstrates the hottest topics, themes, and insights surrounding the art, science, and business of cinema - from capture through to exhibition. As well as being the home of the Big Screen programme, the auditorium will screen in Dolby Vision and Dolby Atmos, Baby Driver, the acclaimed Edgar Wright feature from 2017. The programme for 2017, which has been shaped by a committee of global industry professionals, is an insightful examination of the future of cinema. From virtual reality in cinema to laser and camera assessments, visitors will get up to speed

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom